IL1B and melanoma: Accordingly, in the mouse melanoma model B16F10, it has been recently shown that IL-1β administration to the host may exert adjuvant effects on the expansion and cytotoxic capacities of T cells in patients that are irresponsive (or poorly responders) to adoptive cell therapies (ACTs) [16].